ReStore Exo-Suit Publications Demonstrate Improved Walking Outcomes Versus Conventional Stroke Therapy
MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, March 08, 2024 (GLOBE NEWSWIRE) -- ReWalk Robotics Ltd. (DBA Lifeward™), (Nasdaq: LFWD) (“Lifeward” or the “Company”), a global market leader delivering life-changing solutions to revolutionize what is possible in rehabilitation, recovery, and the pursuit of life’s passions in the face of physical limitation or disability, today highlighted two recent research publications that demonstrate the effectiveness of the unique propulsion training capabilities of the ReStore Exo-Suit for post-stroke rehabilitation.
- Randomized clinical trial demonstrates significant improvements in walking ability for patients receiving therapy with the ReStore Exo-Suit as compared to a matched control group receiving conventional stroke therapy.
- Additional study demonstrates that the improvements in walking speed and distance following high-intensity gait training with the ReStore Exo-Suit were maintained by individuals post-stroke 4 weeks after the intervention had concluded.
- Combined results highlight the clinical value of the ReStore Exo-Suit and its related breakthrough propulsion-augmenting technologies within the Lifeward product development pipeline.
- The ReStore intervention group demonstrated significant improvements compared to the control group, including a 56% increase in 10-meter walking speed, and a 68% improvement in 6-minute walking distance, and the improved performance was demonstrated to persist at the post-intervention follow up assessment.